본문바로가기

Who We Are

Wellmarker Bio Co., Ltd.(WMBIO) Develops Anticancer Drugs Based on Predictive Biomarkers for Unmet Medical Needs

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center (AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialize in developing predictive biomarkers and first-in-class drugs through profound research know-hows and clinical information from AMC. We strive to bring a better outcome to patients and contribute to the healthy life of a mankind through ‘Research Institute’ that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department, and CMC department.

Areas of Expertise

Our Key Areas of Expertise are Predictive Biomarker Development and Drug Discovery Including Small Molecules and Biologics

We are developing predictive biomarkers and anticancer drugs for solid tumors by utilizing in-house research facilities and clinical information from AMC.

On many occasions, “new drug development” can be said to be a “comprehensive art.” To perform this “comprehensive art”, it requires an amazing storyline, stage setting, and above all, a great actor. In the same way, WMBIO continues to make ceaseless effort on developing new drugs by working together with global partners. We will continue to strive in contributing to the healthy life of mankind.

Company History

  • 연혁 2016년 이미지
    2016.

    12Company Founded

  • 연혁 2017년 이미지
    2017.

    04R&D Center Established

    05Pipeline WM-S1(Small Molecule, Colon Cancer)
    Has Been Selected by KDDF    * KDDF: Korea Drug Development Fund

    06Startup R&D Support Program Selected by MSS* MSS: Ministry of SMEs and Startups

    07Acquired the Venture Business Certification

    10Research Collaboration Agreement with Y-Biologics

  • 연혁 2018년 이미지
    2018.

    02Pipeline WM-A1(Therapeutic Antibody, Lung Cancer) Has Been Selected by KDDF

    07WM-S1 Poster Presentation at AACR Annual Meeting* AACR: American Association for Cancer Research

    07WM-A1 Poster Presentation at AACR Annual Meeting

    10Completed Series A($28million)

    11Startup R&D Support Program Selected by MSS [Academy]

    11Company Presentation at the 5th BioCentury China Healthcare Summit

  • 연혁 2019년 이미지
    2019.

    02MOU Signed with KIRAMS(Korea Institute for Radiological and Medical Sciences)

    03MOU Signed with Ukrainian National Medical Institutions (VNMU/PRCO)

    03Pipeline WM-S1 Has Been Selected as a KDDF Follow-up Project

    06MOU Signed with Cytogen for Companion Diagnostics

    07Signed Technology Transfer Contract with KIRAMS(L/I)

    07Completed Series B($18million)

    10MOU Signed with Azothbio

    10Received the Grand Prize at the ‘2019 5th Korean Good Company Awards’ in Bio Sector

  • 연혁 2020년 이미지
    2020.

    03Research Collaboration Agreement with AzothBio on AI-based Anticancer Drug Development

    05Branch Research Center(CMC Center) Established

    05Startup R&D Support Program Selected by MSS [Technology Commercialization]

    05WM-S1 Poster Presentation at ASCO Annual Meeting (with Cytogen)*ASCO: American Society of Clinical Oncology

    10Received the Grand Prize at the ‘2020 6thKorean Good Company Awards’ in Bio Sector for 2 Consecutive Years

    12WM-S1 Phase I Clinical Trial Submission(Australian TGA)* TGA: Therapeutic Goods Administration

  • 연혁 2021년 이미지
    2021.

    02WM-S1 Phase I Clinical Trial Approval(TGA)

    04WM-A1 Poster Presentation at AACR Annual Meeting

    06R&D Center Designated as an 'Excellent Corporation R&D Center' by the Ministry of Science and ICT of Korea

    08Completed Series C($14million)

    09WMBIO receives Innobiz(Innovation + Business) certification from the Ministry of SMEs

Organizational Structure

See more

Collaborations

Wellmarker Bio is Committed to Developing New Drugs through
Continuous Cooperation with Global Partners